Reported 1 day ago
Wolfe Research has raised the price target for Johnson & Johnson (JNJ) from $175 to $195 while keeping its Outperform rating, citing increased confidence in the company's upcoming talc litigation. Despite challenges facing the pharmaceutical sector, Wolfe maintains a positive outlook on J&J's growth prospects, particularly in its Innovative Medicine division.
Source: YAHOO